Cargando…

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)

Detalles Bibliográficos
Autores principales:	Brahmer, Julie, Balmanoukian, Ani, Goldberg, Sarah, Ou, Sai-Hong, Blake-Haskins, Andrew, Karakunnel, Joyson, Stockman, Paul, Rizvi, Naiyer, Antonia, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288573/ http://dx.doi.org/10.1186/2051-1426-2-S3-P179

Ejemplares similares

Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
por: Rizvi, Naiyer, et al.
Publicado: (2015)

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
por: Rizvi, Naiyer, et al.
Publicado: (2015)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
por: Papadopoulos, Kyriakos P, et al.
Publicado: (2015)

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
por: Yang, Hui, et al.
Publicado: (2018)

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
por: Shiraishi, Yoshimasa, et al.
Publicado: (2022)

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
por: Gilbert, Jill, et al.
Publicado: (2015)

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
por: Ngoi, Natalie YL, et al.
Publicado: (2020)

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
por: Ferris, Robert L, et al.
Publicado: (2015)

Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
por: Hanna, Catherine R., et al.
Publicado: (2021)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
por: Naing, Aung, et al.
Publicado: (2019)

Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
por: Hanna, Catherine R., et al.
Publicado: (2021)

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
por: Hegi-Johnson, Fiona, et al.
Publicado: (2022)

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)
por: Ishii, Hidenobu, et al.
Publicado: (2022)

Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
por: Cohen, Ezra EW, et al.
Publicado: (2015)

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018)

‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
por: Rotman, J., et al.
Publicado: (2018)

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results
por: Okonogi, Noriyuki, et al.
Publicado: (2023)

Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study
por: Okonogi, Noriyuki, et al.
Publicado: (2022)

Medi-wiki worries?
por: Mason, Fred
Publicado: (2009)

MediNet: transfer learning approach with MediNet medical visual database
por: Reis, Hatice Catal, et al.
Publicado: (2023)

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
por: Shire, Norah J., et al.
Publicado: (2020)

Art, ciéncia i medi natural.
Publicado: (1994)

Medie and Info-pubmed: 2010 update
por: Ohta, Tomoko, et al.
Publicado: (2010)

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
por: Voss, Martin H., et al.
Publicado: (2022)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie R., et al.
Publicado: (2018)

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
por: Grigg, Claud, et al.
Publicado: (2016)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

MediVisión 3.2 para Windows.

Chocolate in History: Food, Medicine, Medi-Food
por: Lippi, Donatella
Publicado: (2013)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC
por: Aerts, Hugo J. W. L., et al.
Publicado: (2016)

Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
por: Matsubara, Taichi, et al.
Publicado: (2021)

Challenging the Cost Effectiveness of Medi-Cal Managed Care
por: Riner, R. Myles
Publicado: (2009)

Targeting CD73 in the tumor microenvironment with MEDI9447
por: Hay, Carl M., et al.
Publicado: (2016)

Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC
por: Aerts, Hugo J. W. L., et al.
Publicado: (2017)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
por: Yang, Wenchao, et al.
Publicado: (2022)

Circular RNA 0060745, a Novel circRNA, Promotes Colorectal Cancer Cell Proliferation and Metastasis Through miR-4736 Sponging
por: Wang, Xuebing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3c4c2oaivb9qm1glmkgpgns6t